Boston Partners Grows Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Boston Partners increased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 14.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 630,368 shares of the biopharmaceutical company’s stock after buying an additional 77,976 shares during the quarter. Boston Partners owned about 0.50% of Halozyme Therapeutics worth $25,500,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in HALO. Rise Advisors LLC purchased a new stake in shares of Halozyme Therapeutics during the 1st quarter valued at approximately $25,000. Whittier Trust Co. acquired a new stake in Halozyme Therapeutics in the 1st quarter valued at approximately $27,000. Principal Securities Inc. acquired a new stake in Halozyme Therapeutics in the 4th quarter valued at approximately $34,000. Fidelis Capital Partners LLC acquired a new stake in Halozyme Therapeutics in the 1st quarter valued at approximately $52,000. Finally, First Horizon Advisors Inc. increased its holdings in Halozyme Therapeutics by 24.5% in the 4th quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 293 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Down 1.7 %

Shares of HALO stock traded down $0.96 on Friday, reaching $54.09. 1,178,383 shares of the stock were exchanged, compared to its average volume of 1,243,255. The company has a current ratio of 6.64, a quick ratio of 5.36 and a debt-to-equity ratio of 8.44. The business’s 50 day moving average price is $51.28 and its 200 day moving average price is $43.39. The company has a market capitalization of $6.88 billion, a price-to-earnings ratio of 22.35, a PEG ratio of 0.56 and a beta of 1.27. Halozyme Therapeutics, Inc. has a twelve month low of $32.83 and a twelve month high of $57.08.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.07. The firm had revenue of $195.88 million during the quarter, compared to the consensus estimate of $201.72 million. Halozyme Therapeutics had a net margin of 36.94% and a return on equity of 225.71%. As a group, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 3.66 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $45.38, for a total value of $453,800.00. Following the completion of the transaction, the senior vice president now owns 168,176 shares in the company, valued at $7,631,826.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 5,000 shares of the company’s stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $53.93, for a total value of $269,650.00. Following the completion of the transaction, the chief financial officer now owns 15,480 shares in the company, valued at $834,836.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $45.38, for a total transaction of $453,800.00. Following the completion of the transaction, the senior vice president now owns 168,176 shares of the company’s stock, valued at approximately $7,631,826.88. The disclosure for this sale can be found here. Over the last quarter, insiders sold 45,000 shares of company stock worth $2,294,050. Corporate insiders own 2.40% of the company’s stock.

Analysts Set New Price Targets

HALO has been the subject of several research reports. Piper Sandler downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their target price for the company from $48.00 to $51.00 in a report on Friday, June 7th. Wells Fargo & Company lifted their target price on shares of Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a report on Friday, June 7th. HC Wainwright reiterated a “buy” rating and issued a $65.00 target price on shares of Halozyme Therapeutics in a report on Thursday. Benchmark boosted their price target on shares of Halozyme Therapeutics from $50.00 to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. Finally, JMP Securities dropped their price target on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 8th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $58.38.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.